Tech Transfer Roundup: UM Ventures' Deal-Making Priority Is Flexibility
Now providing seed and venture funding for some of its start-ups, University of Maryland's tech transfer has expanded its capabilities in recent years. Plus, our monthly roundup of private/public-sector transactions.
You may also be interested in...
Lilly plans a head-to-head study of donanemab versus Biogen’s Aduhelm to see which clears amyloid plaque better and has begun a rolling BLA toward accelerated approval of the Alzheimer’s drug.
For the third quarter of 2021, biopharmas brought in an aggregate $17.4bn in financing and device company fundraising totaled $3.4bn; while in vitro diagnostic firms and research tools players raised $2.5bn.
Metacrine halts development of its FXR agonist compounds in NASH and turn its focus to inflammatory bowel disease. Firm plans Phase II ulcerative colitis study in 2022 with MET642.